Shares of Acrivon Therapeutics advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for ovarian and endometrial cancers.
More Stories
Apollo reportedly offers Intel a multibillion-dollar investment
Apollo Global Management Inc. has offered to make an investment in Intel Corp. of as much as $5 billion, Bloomberg...
TSMC, Samsung reportedly consider building huge chip factories in UAE
Chip-making titans Taiwan Semiconductor Manufacturing Co. and Samsung Electronics Co. are considering building major factories in the United Arab Emirates...
The Fed’s rate cut should make it easier to get a job — eventually. Here are the industries that could ramp up hiring first.
Some sectors are more likely to pick up hiring as borrowing costs fall. Here’s what that could look like.
Investors cheer a soft landing scenario after Fed’s big rate cut. But they’re still keeping their guard up for a downturn.
The Federal Reserve finally gave stock-market investors what they wanted this week by cutting interest rates for the first time...
As third-quarter earnings approach, here are the stocks that analysts like — and dislike — the most
This summer, shares of Amazon.com Inc., Microsoft Corp. and Nvidia Corp. each took a hit after the technology giants reported...